Skip to main content
Premium Trial:

Request an Annual Quote

Henry Schein Inks US Distribution Deal for SD Biosensor's Coronavirus Antibody Test

NEW YORK — Henry Schein said on Thursday that it has signed an agreement to distribute SD Biosensor's point-of-care immunochromatography test for SARS-CoV-2 in the US.

According to Henry Schein, the Standard Q COVID-19 IgM/IgG Rapid Test is designed for the qualitative presumptive detection of specific IgM and IgG antibodies to SARS-CoV-2 in a fingerstick blood sample. Results are available within 15 minutes with no instrumentation required.

Henry Schein said the test is being made available under emergency guidance from the US Food and Drug Administration. The Melville, New York-based company said that it expects to have at least several hundred thousand tests available by Monday, with greater availability in April.

The test is manufactured by South Korea's SD Biosensor, which is represented in the US by VelocityDx. Henry Schein said that it plans to sign agreements for additional COVID-19 tests from VelocityDx and other suppliers.